Pathology & Oncology Research

, Volume 25, Issue 2, pp 611–624 | Cite as

Prognostic and Clinic-Pathological Significances of SCF and COX-2 Expression in Inflammatory and Malignant Prostatic Lesions

  • Mohamed Ali Alabiad
  • Ola A. HarbEmail author
  • Heba F. Taha
  • Basant Sh El Shafaay
  • Loay M. Gertallah
  • Nashaat Salama
Original Article


The initiation of prostatic malignancy has been linked to chronic inflammation. Stem cell factor (SCF) is an inflammatory cytokine that is specific to the c-KIT receptor which is type III receptor tyrosine kinase (RTK). Cyclooxygenases (COXs) are the main enzymes which are responsible for prostaglandins production from arachidonic acid. COX2 is an enzyme which is produced under different pathological conditions. The aim of our study; is to investigate the clinicopathological and the prognostic significance of SCF and COX-2 expression in prostatic adenocarcinoma (PC), chronic prostatitis and nodular prostatic hyperplasia (NPH) in a trial to clarify the role of inflammation as a risk factor for prostatic carcinogenesis and cancer progression. SCF and COX-2 tissue protein expression were evaluated in 50 cases of PC, 20 cases of chronic prostatitis and 10 cases of NPH using immunohistochemistry, patients were followed up for 5 years. The relationship between their levels of expressions, clinicopathological, and prognostic criteria were studied. SCF expression in PC was positively correlated with advanced patient age (p = <0.001), high level of PSA (p = 0.010), higher Gleason score (p = 0.011). COX-2 expression in PC was positively correlated with advanced patient age (p = <0.001), high level of PSA (p = 0.016), advanced D’Amico risk group (p = 0.038). High levels of expression of both SCF& COX-2 are associated with higher incidence of tumor relapse, worse disease overall survival and free survival (p < 0.001). SCF and COX-2 are associated with PC progression and associated with poor prognosis in PC patients.


SCF COX-2 Prostatic adenocarcinoma Immunohistochemistry Prognosis 


Compliance with Ethical Standards

Conflict of Interest

Authors had declared no conflict of interest.


  1. 1.
    Xu F, Li M, Zhang C, Cui J, Liu J, Li J, Jiang H (2017) Clinicopathological and prognostic significance of COX-2 Immunohistochemical expression in breast Cancer: a meta-analysis. Oncotarget 8(4):6003–6012. CrossRefPubMedGoogle Scholar
  2. 2.
    Yoo S, Se YC, You D, Kim CS (2016) New drugs in prostate Cancer. Prostate International 4(2):37–42. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M et al (2016) Prostate Cancer. N Engl J Med 58(1):1–6. CrossRefGoogle Scholar
  4. 4.
    Lee KC, Cho IR (2017) Chronic prostatitis/chronic pelvic pain syndrome in adolescents compared with that in young adults. Investigative and clinical urology 58(4):267–270CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cardoso HJ, Figueira MI, Socorro S (2017) The stem cell factor (SCF)/c-KIT signaling in testis and prostate cancer. Journal of cell communication and signaling 11(4):297–307CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tayel SI, El-Hefnway SM, El Gayed EMA, Abdelaal GA (2017) Association of stem cell factor gene expression with severity and atopic state in patients with bronchial asthma. Respir Res 18(1):21CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Huang, Bo, Zhang Lei, Gui-mei Zhang, Dong Li, Chuanwang Song, Bo Li, Yanyan Liu, et al. 2014. “SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment”. 112 (4): 1269–1279. CrossRefGoogle Scholar
  8. 8.
    Bilani N, Bahmad H, Abou-Kheir W (2017) Prostate cancer and aspirin use: synopsis of the proposed molecular mechanisms. Front Pharmacol 8:145CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bagir EK, Açikalin A, Izol V, Seydaoglu G, Erdogan S (2016) Immunohistochemical Study of Cyclooxygenase-2 Expression in Prostate Carcinoma: It’s Relation with Apoptosis and Angiogenesis. Bulletin of Urooncology 15(4):144–147Google Scholar
  10. 10.
    Hsu SM, Raine L, Fanger HX (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. Journal of Histochemistry & Cytochemistry 29(4):577–580CrossRefGoogle Scholar
  11. 11.
    Siddique HR, Parray A, Zhong W, Karnes RJ, Bergstralh EJ, Koochekpour S, Saleem M (2013) Correction: BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate Cancer. PLoS One 8(6)Google Scholar
  12. 12.
    Wang X, Ren H, Zhao T, Chen J, Sun W, Sun Y, Lang M (2014) Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis 35(10):2283–2290CrossRefPubMedGoogle Scholar
  13. 13.
    Wang X, Dong J, Jia L, Zhao T, Lang M, Li Z, Qin T (2017) HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. Cancer Lett 393:113–124CrossRefPubMedGoogle Scholar
  14. 14.
    Bellone G, Smirne C, Carbone A, Buffolino A, Scirelli T, Prati A, Emanuelli G (2006) KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol 29(4):851–859PubMedGoogle Scholar
  15. 15.
    Gao C, Li S, Zhao T, Chen J, Ren H, Zhang H, Zhao X (2015) SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression. PLoS One 10(3):e0121338CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yasuda A, Sawai H, Takahashi H, Ochi N, Matsuo Y, Funahashi H, Sato M, Okada Y, Takeyama H, Manabe T (2006) The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic Cancer cells. Mol Cancer 5:46. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, Bevilacqua G, Buchler MW, Friess H (2002) The stem cell factor-c-kit system and mast cells in human pancreatic Cancer. Lab Investig 82(11):1481–1492. CrossRefPubMedGoogle Scholar
  18. 18.
    Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Silvestrini R (2004) C-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat 83(1):33–42CrossRefPubMedGoogle Scholar
  19. 19.
    Eberle F, Leinberger FH, Saulich MF, Seeger W, Engenhart-Cabillic R, Hänze J, Hattar K, Dikomey E, Subtil FSB (2017) In Cancer cell lines inhibition of SCF/c-kit pathway leads to Radiosensitization only when SCF is strongly over-expressed. Clinical and Translational Radiation Oncology 2:69–75. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Krishnamachary B, Stasinopoulos I, Kakkad S, Penet MF, Jacob D, Wildes F, Bhujwalla ZM (2017) Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget 8(11):17981CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wang W, Bergh A, Damber JE (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11(9):3250–3256CrossRefPubMedGoogle Scholar
  22. 22.
    Hu Z, Yang Y, Zhao Y, Huang Y (2017) The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis. OncoTargets and therapy 10:2893–2901CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zha S, Sauvageot J, Ewing CM, Faith DA, Nelson WG, Isaacs WB, Gage WR, Saria EA, Putzi MJ, De Marzo AM (2001) Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61(24):8617–8623PubMedGoogle Scholar
  24. 24.
    Malaysiana S, Siklooksigenase PT, Prostat A, Gred M, National Cancer Registry (2015) High expression of Cyclooxygenase-2 in high grade human prostate adenocarcinoma. In: 44 (5): 727–33Google Scholar
  25. 25.
    Khor LY, Bae K, Pollack A, Elizabeth H Hammond M, Grignon DJ, Venkatesan VM, Rosenthal SA et al (2007) COX-2 expression predicts prostate-Cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8(10):912–920. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Richardsen E, Uglehus RD, Due J, Busch C, Busund LT (2010) COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-β, IL-10 and, Ki67. Cancer Epidemiol 34(3):316–322CrossRefPubMedGoogle Scholar
  27. 27.
    Xu F, Li M, Zhang C, Cui J, Liu J, Li J, Jiang H (2017) Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis. Oncotarget 8(4):6003–6012CrossRefPubMedGoogle Scholar
  28. 28.
    Mukherjee R, Edwards J, Underwood MA, Bartlett JM (2005) The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer. BJU Int 96(1):62–66CrossRefPubMedGoogle Scholar
  29. 29.
    Ceylan Y, Lekili M, Muezzinoglu T, Nese N, Isisag A (2016) Predictive value of cyclooxygenase-2 over-expression for identifying prostate cancer from benign prostatic hyperplasia in prostate biopsy specimens. Minerva urologica e nefrologica= The Italian journal of urology and nephrology 68(3):255–262PubMedGoogle Scholar
  30. 30.
    Khodier MM, Mohmoud SA, Gabal SM, Abou-Sriea MA (2009) Cyclooxygenase-2 (COX-2) expression in Egyptian cases of benign prostatic hyperplasia and prostatic adenocarcinoma. Acad J Cancer Res 2(1):33–39Google Scholar
  31. 31.
    Kim BH, Kim CI, Chang HS, Choe MS, Jung HR, Kim DY, Park CH (2011) Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? Korean journal of urology 52(4):253–259CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GWH, Lalani EN (2000) Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 86(6):736–741CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  1. 1.Pathology Department, Faculty of MedicineZagazig UniversityZagazigEgypt
  2. 2.Medical Oncology Department, Faculty of MedicineZagazig UniversityZagazigEgypt
  3. 3.Clinical Oncology and Nuclear Medicine Department, Faculty of MedicineZagazig UniversityZagazigEgypt
  4. 4.General Surgery Department, Faculty of MedicineZagazig UniversityZagazigEgypt
  5. 5.Urology Department, Faculty of MedicineZagazig UniversityZagazigEgypt

Personalised recommendations